Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 4, 2011, Pages 781-785

  Ready, Neal ^a   Karaseva, Nina A ^b   Orlov, Sergey V ^c   Luft, Alexander V ^d   Popovych, Olexandr ^e   Holmlund, Jon T ^f   Wood, Brian A ^f   Leopold, Lance ^f  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b City Oncology Dispensary St Petersburg   (Russian Federation)

^c State Higher Educational Institution   (Russian Federation)

^d Leningrad Regional Clinical Hospital   (Russian Federation)

^e Donetsk Regional Antitumor Center   (Ukraine)

^f Ascenta Therapeutics   (United States)

Author keywords

Apoptosis; AT 101; Bcl 2; Docetaxel; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ERLOTINIB; ETOPOSIDE; GEMCITABINE; ISOSORBIDE; PACLITAXEL; PEMETREXED; PLACEBO; VINCRISTINE;

ADD ON THERAPY; ADULT; ANEMIA; ARTICLE; ASTHENIA; CANCER GROWTH; DISTANT METASTASIS; DOUBLE BLIND PROCEDURE; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERMAGNESEMIA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SMALL INTESTINE OBSTRUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 79953025265     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31820a0ea6     Document Type: Article

References (15)

1. Chipuk JE, Moldoveanu T, Llambi F, et al. The BCL-2 family reunion. Mol Cell 2010;37:299-310.
2. Lomonosova E, Chinnadurai G. BH3-only proteins in apoptosis and beyond: an overview. Oncogene 2008;27(Suppl 1):S2-S19.
3. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007;26:1324-1337. (Pubitemid 46328466)
4. Letai A. BH3 domains as BCL-2 inhibitors: prototype cancer therapeu-tics. Expert Opin Biol Ther 2003;3:293-304. (Pubitemid 36458760)
5. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apo-ptotic pathways in cancer therapy. Clin Cancer Res 2009;15:1126-1132.
6. Zietlin B, Joo E, Dong Z, et al. Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2. Cancer Res 2006;66:8698-8706. (Pubitemid 44449186)
7. Zietlin BD, Zeitlin IS, Nor JE. Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents. J Clin Oncol 2008;26:4180-4188.
8. MacVicar GR, Reeves J, et al: An open-label, multicenter, phase I/II study ofAT-101 in combination with docetaxel (D) and prednisone (P) in men with hormone refractory prostate cancer (HRPC). J Clin Oncol 2009;27:15s (suppl; abstr 5062).
9. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103. (Pubitemid 30324363)
10. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-2362. (Pubitemid 30415821)
11. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597. (Pubitemid 41079796)
12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organiza-tion for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
13. Chang JT, Carvalho C, Mori S, et al. A genomic strategy to elucidate modules of oncogenic pathway signaling networks. Mol Cell 2009;34:104-114.
14. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-357. (Pubitemid 43128862)
15. Bild AH, Potti A, Nevins JR. Linking oncogenic pathways with thera-peutic opportunities. Nat Rev Cancer 2006;6:735-741. (Pubitemid 44304232)